Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Patients in the CVC group were older and had lower albumin, BUN, and serum P levels as well as higher NT-proBNP (P < 0.05).Baseline characteristics of the CVC group and non-CVC groupCharacteristicCVC(n = 74)Non-CVC(n = 150) P Male [n(%)]42(56.8)106(70.7) < 0.05Age(year)68.9 ± 9.951.8 ± 13.9 < 0.05Dialysis duration (m,\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\overline{\mathrm{x} }$$\end{document}x¯±s)*21.9 ± 8.317.4 ± 7.7 < 0.05BMI(kg/m2,‾x ± s)22.93 ± 3.1523.22 ± 3.450.549CVD [n(%)]20(27.0)24(16.0)0.051DM [n(%)]18(24.3)37(24.7)0.955HBP [n(%)]71(95.9)147(98.0)0.399Smoking [n(%)]4(5.4)23(15.3) < 0.05RBC(× 10^12/L,‾x ± s)3.70 ± 0.633.74 ± 0.540.573Hb (g/L,‾x ± s)109.7 ± 15.5111.6 ± 15.30.407Plt (× 10^9/ L,‾x ± s)192.9 ± 54.1199.1 ± 54.50.426albumin(g/L,‾x ± s)36.4 ± 3.738.70 ± 3.2 < 0.05BUN (mmol/L,‾x ± s)22.5 ± 6.025.3 ± 6.0 < 0.05SCr (μmol/L,‾x ± s)896.9 + 216.61089.7 ± 268.1 < 0.05Ca (mmol/ L,‾x ± s)2.26 ± 0.282.32 ± 0.250.105P (mmol/L,‾x ± s)1.88 ± 0.622.11 ± 0.66 < 0.05iPTH(pg/ml,‾x ± s)379.7 ± 319.2365.0 ± 268.60.72325(OH)D(nmol/L)30.2(21.2 ~ 44.1)26.3(18.8 ~ 39.1)0.118TC(mmol/L,‾x ± s)4.19 ± 0.894.23 ± 1.000.880HDL-C (mmol/L,‾x ± s)1.05 ± 0.401.06 ± 0.340.961LDL-C (mmol/L,‾x ± s)2.51 ± 0.762.46 ± 0.870.827NT-proBNP(pg/ml)4854(2163 ~ 10,345)3065(1568 ~ 6009) < 0.05hsCRP(mg/L,‾x ± s)6.39 ± 10.106.50 ± 9.230.936Primary renal disease [n(%)] CG21(28.4%)69(46.0%) < 0.05 DN12(16.2%)26(17.3%)0.834 HN7(9.5%)5(3.3%)0.055 PKD7(9.5%)10(6.7%)0.458 Other23(31.1%)40(26.7%)0.131 BMI Body mass index, CVD Cardiovascular disease, DM Diabetes mellitus, RBC Red blood cells, Hb Haemoglobin, Plt Platelets, BUN Blood urea nitrogen, iPTH Intact parathyroid hormone, 25(OH)D 25-hydroxy vitamin D, TC Total cholesterol, HDL High-density lipoprotein cholesterol, LDL Low-density lipoprotein cholesterol, NT-proBNP N-terminal brain natriuretic peptide, CRP High-sensitivity C-reactive protein, CG Chronic glomerulonephritis, DN Diabetic nephropathy, HN Hypertensive nephropathy, PKD Polycystic kidney disease, Other Lupus nephritis, gouty nephropathy, nephrotuberculosis, chronic interstitial nephritis, lipoprotein glomerulopathy and so on
Source: Baseline characteristics of the cohort. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cohort study.
Cohort study
Examines exposures and outcomes over time within a defined group.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The patients were followed for a median of 4 years for all-cause mortality and cardiovascular mortality.
Source: Abstract.
This prospective cohort study recruited 224 patients who began HD therapy at the Blood Purification Center, Zhongshan Hospital, Fudan University, from January 1, 2010 to October 31, 2012.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Predictive role of cardiac valvular calcification in all-cause mortality of Chinese initial haemodialysis patients: a follow-up study of 4 years
Cohort study · BMC Nephrology · 2023
Original publication title
Predictive role of cardiac valvular calcification in all-cause mortality of Chinese initial haemodialysis patients: a follow-up study of 4 years
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Cardiac valvular calcification (CVC) is prevalent in haemodialysis (HD) patients. Its association with mortality in Chinese incident haemodialysis (IHD) patients remains unknown.
Source: BackgroundAbstract: What methods does the paper describe?
A total of 224 IHD patients who had just begun HD therapy at Zhongshan Hospital, Fudan University, were enrolled and divided into two groups according to the detection of cardiac valvular calcification (CVC) by echocardiography. The patients were followed for a median of 4 years for all-cause mortality and cardiovascular mortality.
Source: MethodsAbstract: Results
During follow-up, 56 (25.0%) patients died, including 29 (51.8%) of cardiovascular disease. The adjusted HR related to all-cause mortality was 2.14 (95% CI, 1.05 to 4.39) for patients with cardiac valvular calcification. However, CVC was not an independent risk factor for cardiovascular mortality in patients who had just begun HD therapy.
Source: ResultsAbstract: Conclusion
CVC at baseline is an independent risk factor for all-cause mortality in HD patients and makes an independent contribution to the prediction of all-cause mortality. These findings support the use of echocardiography at the beginning of HD.
Source: ConclusionAuthors’ abstract
Background
Cardiac valvular calcification (CVC) is prevalent in haemodialysis (HD) patients. Its association with mortality in Chinese incident haemodialysis (IHD) patients remains unknown.
Methods
A total of 224 IHD patients who had just begun HD therapy at Zhongshan Hospital, Fudan University, were enrolled and divided into two groups according to the detection of cardiac valvular calcification (CVC) by echocardiography. The patients were followed for a median of 4 years for all-cause mortality and cardiovascular mortality.
Results
During follow-up, 56 (25.0%) patients died, including 29 (51.8%) of cardiovascular disease. The adjusted HR related to all-cause mortality was 2.14 (95% CI, 1.05 to 4.39) for patients with cardiac valvular calcification. However, CVC was not an independent risk factor for cardiovascular mortality in patients who had just begun HD therapy.
Conclusion
CVC at baseline is an independent risk factor for all-cause mortality in HD patients and makes an independent contribution to the prediction of all-cause mortality. These findings support the use of echocardiography at the beginning of HD.
Publication and source details
Original title: Predictive role of cardiac valvular calcification in all-cause mortality of Chinese initial haemodialysis patients: a follow-up study of 4 years
Yun Cheng; Zhihui Lu; Xuesen Cao; Xiaoqiang Ding; Jianzhou Zou; Huimin Jin
BMC Nephrology · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Project of Key Medical Discipline of Pudong Hospital of Fudan UniversityZdxk2020 -10Zdxk2020 -10Cheng Yun Jin HuiminRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T20:32:58.789893+00:00
DOI: 10.1186/s12882-023-03076-7 · PMC9933363